Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05947019
Other study ID # QX-2022-A-014
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 1, 2023
Est. completion date October 1, 2025

Study information

Verified date July 2023
Source Shanghai Eye Disease Prevention and Treatment Center
Contact He Jiangnan
Phone 021-62539696
Email hejiangnan85@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical study is to confirm the effectiveness and safety of low-level monochromatic red-light for high myopia control in adults


Description:

Currently, there is still a lack of effective methods for managing adult high myopia globally. The Elsing Myopia and Amblyopia Therapy Instrument, developed by Suzhou Industrial Park Zuoguan Medical Equipment Co., Ltd., has gained widespread usage in mainland China for amblyopia treatment and myopia control. This instrument utilizes low-intensity laser therapy (LLLT) for treatment, demonstrating improvements in visual acuity without any local or systemic side effects. The low-intensity laser induces photochemical reactions in the retina, such as enhancing cytochrome C oxidase activity, modulating gene expression to regulate the mitochondrial respiratory chain, and increasing the biological activity of nitric oxide. These mechanisms have been applied in the treatment of age-related macular degeneration and diabetic retinopathy. As the onset of myopia is closely linked to retinal signaling pathways, preliminary test data suggests that the instrument can significantly slow down myopia progression. This study aims to investigate the potential of low-intensity laser therapy in preventing and treating high myopia in adults, providing innovative approaches to mitigate the widespread impact of high myopia.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date October 1, 2025
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. Age between 18 and 40 years, regardless of gender. 2. Presence of myopic refractive error in at least one eye, with myopic lens power after mydriasis exceeding 6.00D, diffusivity less than 2.00D, binocular anisometropia less than 3.00D, and best corrected distance visual acuity of at least 0.6, as well as near visual acuity of at least 0.6. 3. Normal cognitive abilities and language communication skills, capable of actively cooperating with the required treatment. 4. Absence of contraindications for atropine use, such as acute ocular inflammation, dry eye, keratoconus, and diabetes. 5. Written informed consent obtained from the patients. Exclusion Criteria: 1. History of photoallergy, glaucoma, trichiasis syndrome, ocular hypertension, fundus macula lesions, or eye injuries. 2. Corneal curvature examination revealing an average K value of the anterior corneal surface of =45. 3. Presence of systemic diseases (e.g., heart, liver, kidney diseases) and congenital hereditary myopia. 4. Chronic eye diseases, including ocular trauma, strabismus, or previous ocular surgery, as well as allergic conjunctivitis. 5. Previous internal trichiasis, severe corneal opacity, conjunctival infection, or other eye diseases. 6. Neurological diseases, allergies, or contraindications to atropine or other therapeutic drugs. 7. Presence of immune system and systemic diseases such as albinism, psoriasis, nephrotic syndrome, systemic lupus erythematosus, or diabetes. 8. Epilepsy or mental disorders that hinder normal communication. 9. Previous use of other treatments to control myopia progression, such as anticholinergic drugs like atropine within the past 3 months, or participation in other studies involving functional frame lenses, multifocal soft lenses, or similar interventions. 10. Any other situation deemed unsuitable for participation in the study by the researcher.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Myopic amblyopia comprehensive treatment instrument
Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.
Glasses
Optometry with glasses as a routine treatment

Locations

Country Name City State
China Shanghai Eye Disease Prevention & Treatment Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Eye Disease Prevention and Treatment Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in axial length of the left and right eyes The axis of the eye was assessed utilizing the IOL Master (version 5.02, Carl Zeiss, Jena, Germany), which employed simulated eye calibration prior to measurements. To ensure accuracy, three consecutive measurements were taken, and the average value was obtained. If the difference between any two measurements exceeded 0.05mm, a re-measurement was performed. baseline, 30days, 90 days, 180 days
Secondary Changes of equivalent spherical mirror after mydriatic optometry Based on previous experience, this instrument requires a treatment duration of 180 days to demonstrate its preventive and control effects. Therefore, the 180-day data changes will be utilized as the evaluation indicator. baseline, 180 days
See also
  Status Clinical Trial Phase
Completed NCT01658761 - Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes N/A
Enrolling by invitation NCT03666052 - Shanghai Child and Adolescent Large-scale Eye Study -High Myopia Registration
Completed NCT03294967 - Effect of Caffeine on Ocular Circulation in High Myopes N/A
Not yet recruiting NCT05550740 - Repeated Low-Level Red-Light Therapy for Shortening Axial Length N/A
Not yet recruiting NCT05095194 - Influence of Capsular Tension Ring on IOL-capsular Complex After Cataract Surgery in Patients With High Myopia: a Clinical Observation Based on SS-OCT N/A
Suspended NCT02915133 - The Relationship Between Structure and Visual Function in Myopia Foveoschisis
Not yet recruiting NCT05533450 - A Study on the Efficacy and Safety of Multi-focal Scleral Contact Lens N/A
Not yet recruiting NCT05042856 - To Evaluate IOL Position, Clinical Outcome of PanOptix in High Myopic Cataract Patients N/A
Completed NCT03266354 - Changes of the Corneal Endothelial Cell Count After Artisan Phakic Intraocular Lens Implantation
Recruiting NCT05201677 - Improved Operation of Low Intraocular Pressure in Phacoemulsification for Patients With High Myopia Complicated With Cataract N/A
Completed NCT02169635 - Macular Buckle With Three-armed Silicone N/A
Recruiting NCT03533647 - Development and Pathological Changes of High Myopia Among Children and Adolescents in China
Completed NCT06204211 - Genetic Research on High Myopic Individuals in Northern China
Active, not recruiting NCT05691296 - The Monitoring and Intervention of Refractive Changes in Children and Teenagers in Tianjin N/A
Completed NCT03202485 - Comparison Between TICL and ICL+AK for High Myopic Astigmatism N/A
Not yet recruiting NCT05768152 - Repeated Low-Level Red-Light Therapy Shortens Axial Length N/A
Completed NCT00564213 - Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds Phase 4
Active, not recruiting NCT05803174 - Screening and Identification of Biomarkers for High Myopia by a Rapid Method
Completed NCT03174639 - High Myopia Macular Hole and Retinal Detachment Treated With Double ILM Flaps N/A
Not yet recruiting NCT06264830 - 3D Visualization System in Highly Myopic Cataract Operation N/A